Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ5 | P48544 | 5/20 | 0.47 |
| ▸ | KCNJ3 | P48549 | 5/20 | 0.47 |
| ▸ | KCNJ6 | P48051 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 10/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.43 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
| ▸ | PRKX | P51817 | 1/20 | 0.39 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.39 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20916393 | 1.00 | KCNJ5 (0.47) | KCNJ5KCNJ3KCNJ6ALDH1A1LMNA | |
| SCHEMBL20916527 | 0.92 | RAB9A (0.38) | KCNJ5KCNJ3KCNJ6ALDH1A1LMNA | |
| SCHEMBL20916528 | 0.92 | RAB9A (0.38) | KCNJ5KCNJ3KCNJ6ALDH1A1LMNA | |
| SCHEMBL19553065 | 0.90 | KCNJ5 (0.46) | KCNJ5KCNJ3KCNJ6ALDH1A1LMNA | |
| SCHEMBL19553064 | 0.90 | KCNJ5 (0.46) | KCNJ5KCNJ3KCNJ6ALDH1A1LMNA | |
| SCHEMBL20916446 | 0.89 | P2RX4 (0.55) | KCNJ5KCNJ3KCNJ6ALDH1A1LMNA | |
| SCHEMBL20916447 | 0.89 | P2RX4 (0.55) | KCNJ5KCNJ3KCNJ6ALDH1A1LMNA | |
| SCHEMBL20916418 | 0.89 | KCNJ5 (0.42) | KCNJ5KCNJ3KCNJ6ALDH1A1LMNA | |
| SCHEMBL20916419 | 0.89 | KCNJ5 (0.42) | KCNJ5KCNJ3KCNJ6ALDH1A1LMNA | |
| SCHEMBL19552017 | 0.89 | KCNJ5 (0.37) | KCNJ5KCNJ3KCNJ6ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114984003-B | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-115054600-B | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-113082023-B | Pharmaceutical combination of P2X3 inhibitor and P2X4 inhibitor and application thereof | 武汉朗来科技发展有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-11524938-B2 | Aromatic sulfonamide derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-12-13 | — | — | US | disclosed |
| US-20220324807-A1 | AROMATIC SULFONAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-10-13 | — | — | US | disclosed |
| CN-115054600-A | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-114984003-A | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-113082023-A | Pharmaceutical combination of P2X3 inhibitor and P2X4 inhibitor and application thereof | 武汉朗来科技发展有限公司 | 2021-07-09 | — | — | CN | disclosed |
| US-20210179577-A1 | AROMATIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF ISCHEMIC STROKE | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-17 | — | — | US | disclosed |
| EP-3763704-A1 | AROMATIC SULFONAMIDE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2021-01-13 | — | — | EP | disclosed |
| US-10844016-B2 | Aromatic sulfonamide derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-11-24 | — | — | US | disclosed |
| EP-3458443-B1 | AROMATIC SULFONAMIDE DERIVATIVES | Bayer Pharma AG (DE) | 2020-08-19 | — | — | EP | disclosed |
| US-20190119210-A1 | AROMATIC SULFONAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119210-A1 | AROMATIC SULFONAMIDE DERIVATIVES | ARSA, SULT2A1, TPST2 | KCNJ5 1892/4885KCNJ3 2802/4885KCNJ6 2337/4885 |
| US-20220324807-A1 | AROMATIC SULFONAMIDE DERIVATIVES | ARSA, SULT2A1, TPST2 | KCNJ5 1892/4885KCNJ3 2802/4885KCNJ6 2337/4885 |
| US-11524938-B2 | Aromatic sulfonamide derivatives | ARSA, SULT2A1, TPST2 | KCNJ5 1892/4885KCNJ3 2802/4885KCNJ6 2337/4885 |
| US-10844016-B2 | Aromatic sulfonamide derivatives | ARSA, SULT2A1, TPST2 | KCNJ5 1892/4885KCNJ3 2802/4885KCNJ6 2337/4885 |
| US-20210179577-A1 | AROMATIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF ISCHEMIC STROKE | MAPT, TNNI3, SMN1; SMN2 | KCNJ5 2868/4885KCNJ3 3180/4885KCNJ6 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.